Cargando…

Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias

Mitapivat (AG-348) is a novel, first-in-class oral small molecule allosteric activator of the pyruvate kinase enzyme. Mitapivat has been shown to significantly upregulate both wild-type and numerous mutant forms of erythrocyte pyruvate kinase (PKR), increasing adenosine triphosphate (ATP) production...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Samkari, Hanny, van Beers, Eduard J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721383/ https://www.ncbi.nlm.nih.gov/pubmed/34987744 http://dx.doi.org/10.1177/20406207211066070

Ejemplares similares

P1477: MITAPIVAT EFFICACY IN ADULTS WITH PYRUVATE KINASE DEFICIENCY AND BASELINE HEMOGLOBIN LEVELS >10 G/DL
por: Grace, Rachael F., et al.
Publicado: (2023)

P1497: MITAPIVAT IMPROVES IRON OVERLOAD IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED
por: van Beers, Eduard, et al.
Publicado: (2023)

P1473: CLINICALLY RELEVANT HEMOGLOBIN RESPONSE IN ADULTS WITH PYRUVATE KINASE DEFICIENCY TREATED WITH MITAPIVAT – A SUB-ANALYSIS OF THE ACTIVATE TRIAL
por: Al-Samkari, Hanny, et al.
Publicado: (2023)

P1565: MITAPIVAT IMPROVES INEFFECTIVE ERYTHROPOIESIS AND REDUCES IRON OVERLOAD IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY
por: van Beers, E. J., et al.
Publicado: (2022)

P1548: LONG-TERM TREATMENT WITH ORAL MITAPIVAT IS ASSOCIATED WITH NORMALIZATION OF HEMOGLOBIN LEVELS IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY
por: Barcellini, W., et al.
Publicado: (2022)

P1544: BONE MINERAL DENSITY REMAINS STABLE IN PYRUVATE KINASE DEFICIENCY PATIENTS RECEIVING LONG-TERM TREATMENT WITH MITAPIVAT
por: Al-Samkari, H., et al.
Publicado: (2022)

P1735: IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN MITAPIVAT-TREATED PATIENTS WITH PYRUVATE KINASE DEFICIENCY: A DESCRIPTIVE ANALYSIS FROM THE PHASE 3 ACTIVATE TRIAL
por: Kuo, K. H., et al.
Publicado: (2022)

P1543: MITAPIVAT DECREASES THE NEED FOR TRANSFUSIONS SECONDARY TO POORLY TOLERATED ANEMIA AND ACUTE EVENTS COMPARED TO PLACEBO IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE NOT REGULARLY TRANSFUSED
por: Al-Samkari, H., et al.
Publicado: (2022)

Treating pyruvate kinase deficiency with Mitapivat: a short communication
por: Larik, Muhammad Omar, et al.
Publicado: (2023)

The variable manifestations of disease in pyruvate kinase deficiency and their management
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

S116: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON—TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
por: Kuo, K, et al.
Publicado: (2022)

P1424: ONE-YEAR FOLLOW-UP OF A PHASE 2 STUDY OF MITAPIVAT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR THE TREATMENT OF SICKLE CELL DISEASE
por: van Dijk, Myrthe, et al.
Publicado: (2023)

P1522: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
por: Kuo, K. H. M., et al.
Publicado: (2022)

P1546: ACTIVATE-KIDST: MITAPIVAT IN CHILDREN WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED
por: Grace, R. F., et al.
Publicado: (2022)

P1547: ACTIVATE-KIDS: MITAPIVAT IN CHILDREN WITH PYRUVATE KINASE DEFICIENCY WHO ARE NOT REGULARLY TRANSFUSED
por: Grace, R. F., et al.
Publicado: (2022)

Mitapivat reprograms the RBC metabolome and improves anemia in a mouse model of hereditary spherocytosis
por: Matte, Alessandro, et al.
Publicado: (2023)

Mitapivat, a pyruvate kinase activator, improves transfusion burden and reduces iron overload in β-thalassemic mice
por: Mattè, Alessandro, et al.
Publicado: (2023)

P1545: DURABILITY OF HEMOGLOBIN RESPONSE AND REDUCTION IN TRANSFUSION BURDEN IS MAINTAINED OVER TIME IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY TREATED WITH MITAPIVAT IN A LONG-TERM EXTENSION STUDY
por: Grace, R. F., et al.
Publicado: (2022)

Right in time: Mitapivat for the treatment of anemia in α- and β-thalassemia
por: Musallam, Khaled M., et al.
Publicado: (2022)

AG-348 (mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and adenosine triphosphate levels over a broad range of PKLR genotypes
por: Rab, Minke A.E., et al.
Publicado: (2020)

Comorbidities and complications in adults with pyruvate kinase deficiency
por: Boscoe, Audra N., et al.
Publicado: (2021)

A Comprehensive Analysis of the Erythropoietin-erythroferrone-hepcidin Pathway in Hereditary Hemolytic Anemias
por: van Vuren, Annelies J., et al.
Publicado: (2021)

Iron overload in patients with rare hereditary hemolytic anemia: Evidence‐based suggestion on whom and how to screen
por: van Straaten, Stephanie, et al.
Publicado: (2018)

Concomitant Hereditary Spherocytosis and Pyruvate Kinase Deficiency in a Spanish Family with Chronic Hemolytic Anemia: Contribution of Laser Ektacytometry to Clinical Diagnosis
por: Vives Corrons, Joan-Lluis, et al.
Publicado: (2022)

Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency
por: Al-Samkari, Hanny, et al.
Publicado: (2022)

PI-02: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
por: M., VAN DIJK, et al.
Publicado: (2022)

5589320 FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
por: van Dijk, M.J., et al.
Publicado: (2023)

P1501: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
por: van Dijk, M. J., et al.
Publicado: (2022)

P1481: SYSTEMATICALLY REDUCED RED CELL PHOSPHATIDYLSERINE FLIPPASE ACTIVITY IS SUFFICIENT TO INDUCE HEREDITARY HEMOLYTIC ANEMIA
por: van Dijk, Myrthe, et al.
Publicado: (2023)

Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist’s perspective
por: Kritharis, Athena, et al.
Publicado: (2018)

PB2248: CONCOMITANT HEREDITARY SPHEROCYTOSIS AND PYRUVATE KINASE DEFICIENCY IN A SPANISH FAMILY WITH CHRONIC HEMOLYTIC ANEMIA. CONTRIBUTION OF LASER EKTACYTOMETRY TO CLINICAL DIAGNOSIS
por: Vives Corrons, J.-L., et al.
Publicado: (2022)

Red blood cell vesiculation in hereditary hemolytic anemia
por: Alaarg, Amr, et al.
Publicado: (2013)

Recommendations regarding splenectomy in hereditary hemolytic anemias
por: Iolascon, Achille, et al.
Publicado: (2017)

Korean clinical practice guidelines for the diagnosis of hereditary hemolytic anemia
por: Chueh, Hee Won, et al.
Publicado: (2022)

A Unique Monocyte Transcriptome Discriminates Sickle Cell Disease From Other Hereditary Hemolytic Anemias and Shows the Particular Importance of Lipid and Interferon Signaling
por: van Vuren, Annelies J., et al.
Publicado: (2021)

A new paradigm in the diagnosis of hereditary hemolytic anemia
por: Jung, Hye Lim
Publicado: (2013)

Hereditary hemolytic anemia in Korea from 2007 to 2011: A study by the Korean Hereditary Hemolytic Anemia Working Party of the Korean Society of Hematology
por: Park, Eun Sil, et al.
Publicado: (2013)

Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia
por: Parambil, Joseph G., et al.
Publicado: (2021)

Novel insights into the treatment of complement-mediated hemolytic anemias
por: Berentsen, Sigbjørn, et al.
Publicado: (2019)

Protective effect of ethyl pyruvate on mice sperm parameters in phenylhydrazine induced hemolytic anemia
por: Mozafari, Ali Akbar, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ekc11j9hch1ukm2lvlacratl8v